Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | MAPT | P10636 | 7/20 | 0.38 |
| ▸ | LMNA | P02545 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20305914 | 0.91 | ALDH1A1 (0.46) | ALDH1A1MAPTLMNAKMT2ATSHR | |
| SCHEMBL6857750 | 0.90 | ALDH1A1 (0.41) | ALDH1A1MAPTLMNAKMT2ATSHR | |
| SCHEMBL6858197 | 0.80 | MAPT (0.37) | ALDH1A1MAPTLMNAKMT2ATSHR | |
| SCHEMBL2217859 | 0.77 | CYP3A4 (0.38) | — | |
| Hydrochloric Acid SCHEMBL2222269 | 0.77 | CYP3A4 (0.38) | — | |
| SCHEMBL7991122 | 0.76 | MAPT (0.52) | ALDH1A1MAPTLMNAKMT2ATSHR | |
| SCHEMBL13617175 | 0.76 | TSHR (0.42) | ALDH1A1MAPTLMNAKMT2ATSHR | |
| SCHEMBL13607505 | 0.75 | MAPT (0.36) | ALDH1A1MAPTLMNAKMT2ATSHR | |
| SCHEMBL17805650 | 0.75 | PIM1 (0.46) | ALDH1A1MAPTLMNAKMT2ATSHR | |
| SCHEMBL2219949 | 0.74 | ALDH1A1 (0.40) | ALDH1A1MAPTLMNAKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477980-B1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2016-06-08 | — | — | EP | disclosed |
| US-8389560-B2 | HCV protease inhibitors | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2013-03-05 | — | — | US | disclosed |
| US-20110065737-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2011-03-17 | — | — | US | disclosed |
| US-20090286814-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-11-19 | — | — | US | disclosed |
| US-20090286814-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065737-A1 | HCV PROTEASE INHIBITORS | RNASE1, HAVCR2, CTRL | ALDH1A1 814/4885MAPT 3434/4885LMNA 4510/4885 |
| US-20090286814-A1 | HCV PROTEASE INHIBITORS | HAVCR2, SPINT2, RNASE1 | ALDH1A1 982/4885MAPT 3508/4885LMNA 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.